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IMPORTANCE It has previously been demonstrated that immunosuppressed patients with
cutaneous squamous cell cancer of the head and neck (cSCC-HN) treated with surgery and
postoperative radiotherapy have significantly inferior disease-related outcomes compared
with immunocompetent patients, but data on outcomes after disease recurrence are limited.
OBJECTIVES To report survival outcomes in patients with cSCC-HN after disease recurrence
after surgery and postoperative radiotherapy and to investigate the association of immune
status with disease-related outcomes.
DESIGN, SETTING, AND PARTICIPANTS Amulti-institutional study of 205 patients treated at the
Cleveland Clinic, Washington University in St Louis, and the University of California, San
Francisco, in which patients who underwent surgical resection and postoperative
radiotherapy for primary or recurrent stage I to IV (nonmetastatic) cSCC-HN between January
1, 1995, and December 31, 2014, were identified. Patients with any disease recurrence,
defined as local, regional, and/or distant failure, were included. Patients were categorized as
immunosuppressed if they received a diagnosis of chronic hematologic malignant neoplasm
or HIV or AIDS, or were treated with immunosuppressive therapy for organ transplantation
6months or more before diagnosis. Statistical analysis was conducted from January 1, 1995,
to December 31, 2015.
MAIN OUTCOMES ANDMEASURES Overall survival calculated using the Kaplan-Meier method
and compared using the log-rank test.
RESULTS Of the 205 patients in the original cohort, 72 patients (63men and 9women;
median age, 71 years [range, 43-91 years]) developed disease recurrence after surgery and
postoperative radiotherapy. Forty patients (55.6%) were immunosuppressed, and 32 patients
(44.4%) were immunocompetent. Locoregional recurrence was themost common first
pattern of failure for both groups (31 immunosuppressed patients [77.5%]; 21
immunocompetent patients [65.6%]). After any recurrence, 1-year overall survival was
43.2% (95% CI, 30.9%-55.4%), andmedian survival was 8.4months. For patients for whom
information on salvage treatment was available (n = 45), those not amenable to surgical
salvage had significantly poorer median cumulative incidence of survival compared with
those whowere amenable to surgical salvage (4.7 months; 95% CI, 3.7-7.0months vs 26.1
months; 95% CI, 6.6months to not reached; P = .01), regardless of their immune status.
CONCLUSIONS AND RELEVANCE Results of this study suggest that patients with cSCC-HNwho
experience disease recurrence after definitive treatment with surgery and postoperative
radiotherapy have poor survival, irrespective of immune status. Survival rates are low for
patients with recurrent disease that is not amenable to surgical salvage. The low rate of
successful salvage underscores the importance of intensifying upfront treatment to prevent
recurrence.
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C utaneous squamous cell carcinoma (cSCC) has afavorable prognosis, with rates of locoregional recur-rence and distant metastasis less than 5%. However,
there is a subset of patients with adverse pathologic features
and a more aggressive clinical course, with substantially
higher rates of locoregional recurrence (13%-41%) and dis-
tant metastasis (7%-16%) after surgical resection.1-4 Postop-
erative radiotherapy (RT) has been used to optimize locore-
gional control in these patients who are at higher risk for
recurrence.5-9
Despite intensified bimodality therapy, the presence of
features such as deep invasion, perineural invasion, poor
differentiation, positive margins, node-positive disease, and
extracapsular extension have been identified in the litera-
ture as factors associated with inferior outcomes.1-4 A previ-
ous report of a multi-institutional experience of patients
with aggressive cSCC of the head and neck (cSCC-HN)
treated with surgery and postoperative RT demonstrated
that patients who are chronically immunosuppressed have
dramatically lower 2-year locoregional recurrence-free sur-
vival (47.3% vs 86.1%; P < .001) and progression-free sur-
vival (38.7% vs 71.6%; P = .002) compared with patients
who are immunocompetent.10 Building on these data, the
present study further examines the subset of patients with
disease recurrence after surgery and postoperative RT to
identify survival rates after recurrence and determine the
association of immune status with this outcome. We
hypothesized that survival outcomes after disease recur-
rence would be inferior in immunosuppressed patients,
similar to their initial disease-related outcomes.
Methods
This study included patients who underwent surgical resec-
tion and postoperative RT for primary or recurrent cSCC-HN
between January 1, 1995, and December 31, 2014, at the
Cleveland Clinic (Cleveland, Ohio), Washington University
in St Louis (St Louis, Missouri), and the University of Cali-
fornia San Francisco. All patients included in this study
were age 18 years or older and had a histologic diagnosis of
cSCC-HN. Patients with upfront distant metastatic disease,
squamous cell carcinoma (SCC) in situ alone, cSCC of the
trunk or extremities, SCC of unknown primary site, pallia-
tive doses of RT, or inadequate medical records were
excluded. From this larger initial cohort, patients who
developed locoregional or distant recurrence after surgery
and postoperative RT were selected for inclusion in the cur-
rent study. All patients were restaged according to the
American Joint Committee on Cancer, 7th edition, staging
system.10 Surgical resection was by wide local excision or
Mohs micrographic surgery, and was at the discretion of the
treating surgeon. This study was approved by the institu-
tional review boards of the Cleveland Clinic, Washington
University in St Louis, and the University of California San
Francisco. Patient consent for this study was waived by the
institutional review board of each respective institution as
the data were deidentified.
The patients were categorized as immunosuppressed if
they received a diagnosis of chronic hematologic malignant
neoplasm or HIV or AIDS, or were treated with immunosup-
pressive therapy for organ transplantation 6months or more
prior to diagnosis. Organ transplant recipients included those
who receivedkidney,heart, lung, liver, pancreas, or bonemar-
row transplant. Immunosuppressive agents included predni-
sone, cyclosporine, azathioprine sodium, sirolimus, tacroli-
mus, and mycophenolate mofetil.
During the earlier years of the study, electron beam and
3-D conformal RT techniques were used, and in more recent
years of the study, intensity-modulated RT was used. Treat-
ment volumes included the tumor bed in all patients; ipsilat-
eral lymphaticswere included if theywere involvedor thought
to be at risk of microscopic disease. Nerve roots were tar-
geted to the skull base in cases of extensive perineural inva-
sion. Concurrent chemotherapy was administered for select
patients, most commonly in the setting of positive margins
and/or extracapsular extension.
Follow-up includedpostoperative treatment imagingwith
computed tomography or positron emission tomography
3 months after RT and continued multidisciplinary care. Lo-
coregional recurrence was defined as recurrence at the pri-
mary site, resectionmargin, or regional lymphnodes. Distant
failure included failure outside of thehead andneck,most of-
ten in the lungs and other viscera. A subset of 45 patients had
sufficient clinical information after failure to determine
whether salvage surgery was performed.
Statistical analysis was conducted from January 1, 1995,
toDecember31, 2015.Overall survivalwascalculatedusing the
Kaplan-Meier method from the date of local, regional, or dis-
tant recurrence,whicheveroccurred first, andcomparedusing
the log-rank test. All P values were from 2-tailed tests and re-
sults were deemed statistically significant at P ≤ .05. Statisti-
cal analysis was performed using SAS, version 9.4, software
(SAS Institute Inc).
Key Points
Question What are expected survival outcomes for patients with
cutaneous squamous cell carcinoma of the head and neck who
demonstrate locoregional and/or distant disease recurrence after
surgery and postoperative radiotherapy?
Findings In this multi-institutional cohort study, 1-year overall
survival was 43.2% andmedian survival was 8.4months after
disease recurrence; median survival did not differ significantly
between immunosuppressed and immunocompetent patients
(8.0 vs 12.9months). In patients who were not amenable to
surgical salvage, significantly poorer median survival was observed
compared with patients who underwent surgical salvage (4.7 vs
26.1 months), regardless of their immune status.
Meanings Patients with cutaneous squamous cell carcinoma of
the head and neck who experience disease recurrence after
definitive treatment with surgery and postoperative radiotherapy
have poor survival, irrespective of immune status; the low rate of
successful surgical salvage underscores the importance of
intensifying upfront treatment to prevent recurrence.
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Results
The original multi-institutional cohort comprised 205 pa-
tients with cSCC-HN.10 The present analysis includes 72 pa-
tients from this original cohort who demonstrated any local,
regional, and/or distant recurrence after surgery and postop-
erative RT for cSCC-HN. Baseline demographics, tumor char-
acteristics, andpatternsof first failureare included in theTable.
There were 40 patients (55.6%) who were immunosup-
pressed and 32 patients (44.4%) who were immunocompe-
tent. Themedian time to anydisease recurrence after comple-
tion of postoperative RT was 10.1 months (range, 1.4-57.4
months) for immunocompetentpatientsand9.1months (range,
1.0-77.4 months) for immunosuppressed patients; locore-
gional recurrence was the most common first pattern of fail-
ure for both groups (immunosuppressed, 31 [77.5%]; and im-
munocompetent, 21 [65.6%]).
After any recurrence, 1-year overall survival was 43.2%
(95% CI, 30.9%-55.4%) and median survival was 8.4 months
for the entire cohort.Median survival didnot significantlydif-
fer between the immunosuppressed and immunocompetent
groups (8.0months; 95%CI, 4.8-32.3months vs 12.9months;
95%CI, 4.7-57.2months; P = .90) (Figure 1). There were 3 pa-
tients (2 immunosuppressed and 1 immunocompetent) who
survived beyond 5 years after recurrence.
Of the 72 patients included in the study, 27 patients from
1of the3 institutionsdidnothavedata regardingsalvage thera-
pies available for analysis. Of the 45 patients for whom data
on salvage treatment were available, 9 patients were ame-
nable to salvage surgeryowing to limitedextentofdisease and
goodperformance status,with 4 of these patients also under-
goingpostoperative re-irradiation.Of the9patientswhowere
able to undergo salvage surgery, 7 underwent surgical
salvage for local-only recurrence and 2 for nodal-only recur-
rence. There were 36 patients whowere not considered ame-
nable to salvage surgery, owing to disease extent or perfor-
mance status; they received treatment with palliative RT
(n = 21), palliative chemotherapy (n = 4), or cetuximab (n = 2),
or were transferred to hospice care with no further therapy
(n = 9).
Patients who were not amenable to surgical salvage had
significantly poorermedian cumulative incidence of survival
compared with those whowere amenable to surgical salvage
(4.7 months; 95% CI, 3.7-7.0 months vs 26.1 months; 95% CI,
6.6months tonot reached;P = .01) (Figure2). Survivalwasnot
was not significantly different between immunosuppressed
and immunocompetent patients with unsalvageable disease
(3.9 months; 95% CI, 1.3-5.0 months vs 5.0 months; 95% CI,
2.6-14.4months;P = .09) (Figure 3). Patientswhounderwent
salvage surgery alone (n = 5) had a median survival of 32.3
months (95% CI, 9.8-32.3 months), and patients who under-
went salvage surgery and postoperative re-irradiation (n = 4)
had a median survival of 26.1 months (95% CI, 6.6 to not
reached).
Discussion
Outcomes for recurrent cSCC-HN after surgery and postop-
erative RT are not well studied, to our knowledge. This study
demonstrates that survival in this population is poor. Al-
thoughwehypothesizedthat immunosuppressedstatuswould
beasignificant contributor tooutcomes in thesepatients, simi-
lar to findings in the upfront treatment setting,10 the current
Table. Baseline Demographics, Tumor Characteristics,
and Patterns of First Failure
Variable
Patients, No. (%)
Immunocom-
petent (n = 32)
Immunosup-
pressed (n = 40)
Age, median (range), y 73 (43-89) 68 (46-91)
Male sex 26 (81.3) 37 (92.5)
KPS score, median (range) 80 (60-90) 80 (50-90)
Type of immunosuppression
Organ transplant recipient NA 21 (52.5)
Hematologic malignant neoplasm NA 16 (40.0)
HIV NA 3 (7.5)
pT stage
Tx 8 (25.0) 3 (7.5)
T1/T2 11 (34.4) 28 (70.0)
T3/T4 13 (40.6) 9 (22.5)
pN stage
N0 16 (50.0) 27 (67.5)
N1 1 (3.1) 3 (7.5)
N2 12 (37.5) 10 (25.0)
N3 3 (9.4) 0
Time to first recurrence after
postoperative RT, median (range), mo
10.1 (1.4-57.4) 9.1 (1.0-77.4)
Type of first recurrence
Both 4 (12.5) 5 (12.5)
Locoregional 21 (65.6) 31 (77.5)
Distant 7 (21.9) 4 (10.0)
Abbreviations: KPS, Karnofsky Performance Status; NA, not applicable; RT,
radiotherapy.
Figure 1. Overall Survival After Disease Recurrence After Definitive
Surgery and Postoperative Radiotherapy by Immune Status
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Themedian survival time was 12.9months for immunocompetent patients and
8.0months for immunosuppressed patients.
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study suggests that this is not the case. Once cancer recurs in
patientswithhigh-risk cSCC-HNafter surgery andpostopera-
tiveRT,outcomesaresuboptimal, independentof immunesta-
tus. Similar to outcomes among patients in the upfront set-
ting with unresectable disease, survival was poor in patients
with recurrent cSCC-HN who were not amenable to surgical
salvage.Anexception to this observation seems to include the
small number of patients who were amenable to salvage sur-
geryanddemonstrateddramatically improvedsurvival as a re-
sult. Most of our patients already underwent comprehensive
surgery andRT, so the ability to undergo salvage surgerymay
have selected patients who had either less extensive initial
treatment or more limited recurrence with correspondingly
more favorable outcomes.
There are several important implications to these find-
ings. First, the low rates of successful salvage treatment
underscore the importance of intensifying upfront treatment
to prevent recurrence. In addition to surgery and RT, sys-
temic therapy should be considered. There is no level I evi-
dence that supports the use of concurrent systemic therapy
in the upfront management of high-risk cSCC-HN. For de-
cades, oncologistshaveextrapolated fromtheexperiencewith
mucosal head andneck cancer inwhich concurrent cisplatin-
based chemotherapy is a standard of care in resected high-
risk disease with evidence of positive margins and/or extra-
capsular extension.11 Therefore, given its efficacy formucosal
SCC, concurrent cisplatinhasbeenusedbysomefor cSCC.This
speculation was formally tested in the Trans Tasman Radia-
tionOncologyGroup05.01POST trial.12 This trial includedpa-
tients with extracapsular extension, intraparotid nodal dis-
ease, more than 2 cervical lymph nodes, lymph nodes larger
than 3 cm, T3and T4 primary tumor, or in-transitmetastases,
randomized to receive postoperative RT (60-66 Gy) or con-
current postoperativeRTwith 6 cycles ofweekly carboplatin.
Therewasno significant difference in 2-year locoregional fail-
ure-freesurvival (88%vs89%;P = .59),2-yeardisease-freesur-
vival (67% vs 73%; P = .43), and 2-year overall survival (76%
vs79%;P = .84) forpostoperativeRTandpostoperativeRTwith
concurrent chemotherapy.Although this study failed to show
a benefit to the addition of cytotoxic chemotherapy to RT in
the initialmanagementofhigh-riskdisease, somehavepointed
out that the outcomes in the control armwere better than ex-
pectedand that carboplatinmayhavebeenapoor choice com-
pared with cisplatin, as there are data to suggest that single-
agent carboplatinmayhave inferior outcomes comparedwith
cisplatin in the setting of mucosal head and neck SCC.13
A second important lesson from this study is that sys-
temic therapies used for the recurrent andmetastatic setting
have limited efficacy. For patients with metastatic and/or re-
currentcSCC,older studiesdemonstratedmodestefficacywith
cytotoxic chemotherapy and/or retinoic acid regimens, with
response rates in the range of 30% to 35%.14,15 More recently,
targeted agents inhibiting the epidermal growth factor recep-
tor have been studied and shown activity as well. An initial
phase 2 study using gefitinib, an oral tyrosine kinase inhibi-
tor, observed a response rate of 15% and a radiographic dis-
ease control rate of 45% in patients with incurable disease.16
Amore recentphase2 study tested the anti–epidermal growth
factor receptor antibodycetuximabasmonotherapy in the set-
ting of unresectable and metastatic disease.13-15 The primary
end point of the trial, radiographic disease control rate at 6
weeks, was 69%. In addition, they determined an overall re-
sponse rate of 30%, with a complete response rate of 6%.13-15
Although all of these systemic therapy options have some ac-
tivity, their efficacy is limited, which helps explain the poor
survival that we observed in our study.
A new class of agents is now being tested in cSCC and has
shown promising early results. Immune checkpoint inhibi-
tors are a burgeoning class of immunotherapydrugs that have
demonstrated activity inmany cancers andhave shownsome
of the highest response rates in other cutaneous cancers, in-
cluding melanoma and Merkel cell carcinoma.17-20 The most
active agents in this class inhibit the programmed cell death
protein 1 or programmed death-ligand 1 (PD-L1).17,21,22 Initial
results of a phase 1 trial of a PD-L1 inhibitor, cemiplimab, in
patients with recurrent and/ormetastatic cSCCwere recently
reported and showed an overall response rate of 46.2% and a
disease control rate of 69.2% with a median follow-up of 6.9
Figure 2. Overall Survival by Disease Recurrence Among Patients
TreatedWith Salvage Surgery vs No Salvage Surgery
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Themedian survival time was 26.1 months for patients who underwent salvage
surgery and 4.7 months for patients who did not undergo salvage surgery.
Figure 3. Overall Survival After Disease Recurrence for Patients
Not Eligible for Salvage Surgery by Immune Status
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Themedian survival time was 5.0months for immunocompetent patients and
3.9months for immunosuppressed patients.
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months.23 The median progression-free survival and overall
survival were not reached at the data cutoff date, and per-
haps most compelling was the observation that some re-
sponses were quite durable, lasting more than 1 year in some
patients. This study led to the US Food and Drug Administra-
tionapprovalof thisagentas the firstandonlysystemic therapy
specifically for locally advanced cSCC not amenable to surgi-
cal resectionand formetastatic cSCC.These agentsmaybead-
opted as the standard of care for these patients with limited
options otherwise. In addition to the setting of recurrent and
metastatic disease, the significant activity of checkpoint in-
hibitors in this disease provides a strong rationale to incorpo-
ratingthemintheupfrontcurativesetting inpatientswithhigh-
risk disease. An ongoing phase 2 study, NCT 03057613, is
evaluating theadditionofpembrolizumab topostoperativeRT
for patients with high-risk cSCC-HN. This study includes pa-
tients who have undergone a gross total resection with T4 or
node-positive disease, or T2 or T3N0diseasewith 1 of the fol-
lowing additional features: recurrent disease, perineural in-
vasion, lymphovascular space invasion, poor differentiation,
positive margins, or in-transit metastases.24 Further data
regarding these agentsmay help improve outcomes for these
patients. Use of immunotherapy is likely to be limited among
patientswhoare substantially immunocompromised. Specifi-
cally, the use of immunotherapy should be avoided for pa-
tients who have undergone solid-organ transplant given the
risk of organ rejection, whereas its use can still be considered
for patients with chronic lymphocytic leukemia.
Limitations
Limitations of our study include its retrospective design and
small sample size. Furthermore, as the data come from ter-
tiary referral centers, a referral bias may have contributed to
more patients with advanced disease that is not amenable
to further definitive therapy, reflecting poorer outcomes.
Another source of selection bias is that we included only
patients who were candidates for definitive surgery and
postoperative RT in the upfront setting, excluding patients
who received palliative RT, potentially skewing the survival
outcomes to be better than that reflected in this entire
patient population. In addition, the absence of patient data
after failure from 1 of the participating centers reduced the
numbers of patients who could be used for this analysis.
With burgeoning data for immunotherapy in immunocom-
petent patients with advanced disease, the salvage strate-
gies used in this study may not reflect current practice pat-
terns, and outcomes with immunotherapy may be better
than what we have described.
Futuredirectionsof thiswork,with a largerdata set, could
includeananalysisof themost commonpatternsof failureand
their associated risk factors to drive the nature of treatment
intensification upfront, whether it be more extensive pri-
mary surgery,nodaldissection,RTvolumes,or additionof sys-
temic therapy.Furthermore, itwouldbeprudent toexpandthe
study to include more centers to increase the power of this
study. Despite the limitations discussed, our study provides
an important baseline for clinical outcomes after post-RT re-
currence andcanhelp informclinical trial design in this popu-
lation. Most important, it underscores the need for more ef-
fective regimens in this space and the need for additional
clinical trials.
Conclusions
Patientswith cSCC-HNwhoexperiencedisease recurrence af-
terdefinitive treatmentwithsurgeryandpostoperativeRThave
poor survival, irrespective of immune status. Further clinical
trials evaluating the role of concurrent chemotherapy, tar-
geted agents, and immunotherapy are warranted.
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